Epizyme

Epizyme is a biopharmaceutical company located in Cambridge, MA, that is focused on researching treatments for blood cancer and tumors.   Founded in late 2007, the company has brought together premier academic and industry leaders to rapidly translate the exciting discoveries emerging from epigenetic research into specific programs that will produce important, novel, molecularly targeted drugs of the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PARIS, FRANCE & CAMBRIDGE, MASSACHUSETTS, 27 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors and is anticipated to close by the end of the third quarter of 2022, subject to the satisfaction of all closing conditions. Epizyme is a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets for cancer patients.

Ipsen to acquire Epizyme, expanding its portfolio in oncology

PARIS, FRANCE, 5 August 2022 – Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ: EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non-transferable contingent value right (CVR) per Share, until 11:59 p.m., Eastern time on Thursday 11 August 2022, unless further extended. The tender offer was previously scheduled to expire at one minute after 11:59 p.m., Eastern time, on Monday 8 August 2022. All other terms and conditions of the tender offer remain unchanged.

Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 August 2022

PARIS, FRANCE, 12 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company' at deal close.

Ipsen completes acquisition of Epizyme expanding its portfolio in oncology

PARIS--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company' at deal close. As part of the trans

Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology

Epizyme (EPZM) posts a narrower-than-expected loss in the second quarter. Revenues beat estimates.

Epizyme (EPZM) Q2 Earnings Beat Estimates, Revenues Up Y/Y

Epizyme (EPZM) delivered earnings and revenue surprises of 41.67% and 172.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update. “I am pleased with the progress we made as an organization in the second quarter. In addition to the growth of TAZVERIK net product revenue, we are continuing to advance several of our ta

Epizyme Reports Second Quarter 2022 Financial Results and Provides Business Update

PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen S.A. (Euronext: IPN; ADR: IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ: EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non

Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Epizyme, Inc. (NasdaqGS: EPZM) to Ipsen S.A. (OTC: IPSEY). Under the terms of the proposed transaction, shareholders of Epizyme will receive only $1.45 in cash plus a CVR (Contingent Value Right) of $1.00 for each share of Epizyme that they own. KSF is seeking to determine whether this consideration and the pr

EPIZYME INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Epizyme, Inc. - EPZM

Wilmington, Delaware--(Newsfile Corp. - June 28, 2022) - Rigrodsky Law, P.A. is investigating Epizyme, Inc. ("Epizyme") (NASDAQ: EPZM) regarding possible breaches of fiduciary duties and other violations of law related to Epizyme's agreement to be acquired by Ipsen S.A. (OTC Pink: IPSEF). Under the terms of the agreement, Epizyme's shareholders will receive $1.45 in cash and one contingent value right (CVR) of $1.00 for each share of Epizyme common stock they own.To learn more about...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Epizyme, Inc. Merger

NEW YORK , June 27, 2022 /PRNewswire/ --  Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Epizyme, Inc. (EPZM), relating to its proposed acquisition by Ipsen S.A. via a tender offer.

Shareholder Alert - The M&A Class Action Firm Announces an Investigation of Epizyme, Inc. - EPZM

NEW YORK , June 27, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Epizyme, Inc. ("Epizyme" or the "Company") (NASDAQ: EPZM), in connection with the proposed acquisition of the Company by Ipsen S.A. (Euronext: IPN; ADR: IPSEY) via tender offer.

SHAREHOLDER ALERT: Weiss Law Investigates Epizyme, Inc.

A buyout ends Epizyme's 15-year tenure as an independent biopharma.

Why Epizyme Stock Is Soaring Today

Ipsen, through its wholly-owned subsidiary, is set to acquire Epizyme (EPZM) for $1.45 per share, in cash, along with a contingent value right of $1 per share. The transaction is likely to close by third-quarter 2022.

Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen

MILWAUKEE , June 27, 2022 /PRNewswire/ -- Ademi LLP is investigating Epizyme (NASDAQ:EPZM) for possible breaches of fiduciary duty and other violations of law in its transaction with Ipsen.  Click here to learn how to join the action: https://www.ademilaw.com/case/epizyme-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Epizyme, Inc. has obtained a Fair Price in its transaction with Ipsen

Epizyme Inc (NASDAQ: EPZM) shares are trading higher Monday after the company announced it entered into a definitive agreement to be acquired by Ipsen. "We expect that this acquisition and Ipsen's commitment to invest in the oncology space will ensure our epigenetic pipeline continues.

Why Epizyme Shares Are Soaring Today

Epizyme stock is up nearly 65% today on news that the biotechnology company is going to be acquired by French pharmaceutical concern Ipsen. The post Why Is Epizyme (EPZM) Stock Up 75% Today?

Why Is Epizyme (EPZM) Stock Up 75% Today?

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of Epizyme, Inc. (NASDAQ: EPZM) to Ipsen is fair to Epizyme shareholders. Halper Sadeh encourages Epizyme shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Epizyme and its board of directors violated the federal sec

EPZM Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Epizyme, Inc. Is Fair to Shareholders

Ipsen SA (OTC: IPSEY) has agreed to acquire Epizyme Inc (NASDAQ: EPZM) at $1.45 per share for approximately $247 million, plus one contingent value right (CVR) per share.  The deal is expected to close by Q3.

Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why

Ipsen to acquire U.S.-based Epizyme for $247 million.

PARIS & CAMBRIDGE, MASS.--(BUSINESS WIRE)--Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transaction was unanimously approved by both Ipsen and Epizyme Boards of Directors and is anticipated to close by the end of the third quarter of 2022, subject to the satisfaction of all

Ipsen to Acquire Epizyme, Expanding Its Portfolio in Oncology

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?

Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?

NRX Pharmaceuticals

Spectrum Pharma

Trevena

Penny stocks to watch under $1 right now The post Hot Penny Stocks Under $1 To Watch In June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks Under $1 To Watch In June

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, announced updated safety and activity data from the Phase 1b safety run-in portion of its Phase 1b/3 confirmatory study evaluating the investigational use of tazemetostat, a first-in-class, oral, selective inhibitor of EZH2, in combination with rituximab + lenalidom

Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 Combination Study in Relapsed/Refractory Follicular Lymphoma at the 2022 ASCO Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that Grant Bogle, President and Chief Executive Officer, and Shefali Agarwal, Senior Medical Advisor and Interim Chief Medical and Development Officer, will present at the H.C. Wainwright Global Investment Conference. A pre-recorded fireside chat will be a

News for Epizyme Stock (EPZM)